Molecular Biology of the Cell click for CBE Life Science Education Page

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Originally published as MBC in Press, 10.1091/mbc.E08-09-0965 on May 28, 2009

Vol. 20, Issue 14, 3353-3362, July 15, 2009

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Materials
Right arrow All Versions of this Article:
E08-09-0965v1
20/14/3353    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Espina, A. G.
Right arrow Articles by Pintor-Toro, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Espina, A. G.
Right arrow Articles by Pintor-Toro, J. A.

Induction of Dlk1 by PTTG1 Inhibits Adipocyte Differentiation and Correlates with Malignant Transformation

Águeda G. Espina*,{dagger}, Cristina Méndez-Vidal*,{dagger}, Miguel A. Moreno-Mateos*,{dagger}, Carmen Sáez{ddagger}, Ana Romero-Franco*, Miguel A. Japón{ddagger}, and José A. Pintor-Toro*

*Centro Andaluz de Biología Molecular y Medicina Regenerativa, CABIMER-CSIC, 41092 Sevilla, Spain; and {ddagger}Departamento de Anatomía Patológica, Hospital Universitario Virgen del Rocío, 41013 Sevilla, Spain

Submitted September 23, 2008; Revised April 16, 2009; Accepted May 18, 2009
Monitoring Editor: John L. Cleveland

Pituitary tumor-transforming gene-1 (PTTG1) is an oncogene highly expressed in a variety of endocrine, as well as nonendocrine-related cancers. Several tumorigenic mechanisms for PTTG1 have been proposed, one of the best characterized being its capacity to act as a transcriptional activator. To identify novel downstream target genes, we have established cell lines with inducible expression of PTTG1 and a differential display approach to analyze gene expression changes after PTTG1 induction. We identified dlk1 (also known as pref-1) as one of the most abundantly expressed PTTG1 targets. Dlk1 is known to participate in several differentiation processes, including adipogenesis, adrenal gland development, and wound healing. Dlk1 is also highly expressed in neuroendocrine tumors. Here, we show that PTTG1 overexpression inhibits adipogenesis in 3T3-L1 cells and that this effect is accomplished by promoting the stability and accumulation of Dlk1 mRNA, supporting a role for PTTG1 in posttranscriptional regulation. Moreover, both pttg1 and dlk1 genes show concomitant expression in fetal liver and placenta, as well as in pituitary adenomas, breast adenocarcinomas, and neuroblastomas, suggesting that PTTG1 and DLK1 are involved in cell differentiation and transformation.


This article was published online ahead of print in MBC in Press (http://www.molbiolcell.org/cgi/doi/10.1091/mbc.E08-09-0965) on May 28, 2009.

{dagger} These authors contributed equally to this work.

Address correspondence to: José A. Pintor-Toro (jose.pintor{at}cabimer.es)

Abbreviations used: csd, stearoyl-CoA desaturase; IPTG, isopropylthiogalactoside; pttg1, pituitary tumour-transforming gene.







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Copyright © 2009 by The American Society for Cell Biology. Terms of copyright protection, warranties, and disclaimers.